Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CDT Equity Inc. - Common Stock
(NQ:
CDT
)
1.430
-0.160 (-10.06%)
Streaming Delayed Price
Updated: 3:50 PM EST, Dec 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about CDT Equity Inc. - Common Stock
< Previous
1
2
Next >
CDT Equity Increases Bitcoin Holding
October 17, 2025
From
CDT Equity Inc.
Via
GlobeNewswire
CDT Equity Inc. Announces Reverse Stock Split
October 09, 2025
From
CDT Equity Inc.
Via
GlobeNewswire
CDT Executes Cryptocurrency Treasury Reserve Strategy
September 17, 2025
Initial digital asset acquisition marks milestone in capital diversification initiative
From
CDT Equity Inc.
Via
GlobeNewswire
CDT Board Authorizes Adoption of Cryptocurrency Treasury Reserve Strategy
September 03, 2025
Cryptocurrency treasury reserve strategy is designed to diversify capital structure while reinforcing CDT's innovation-led model
From
CDT Equity Inc.
Via
GlobeNewswire
CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy
August 26, 2025
Using AI, CDT Equity Inc. identifies a novel therapeutic indication for its lead programmes, supported by successful pre-clinical trial data
From
CDT Equity Inc.
Via
GlobeNewswire
Conduit to Change Name to CDT Equity Inc.
August 05, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Engages Consultant to Explore Cryptocurrency Reserve Strategy
July 08, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries
July 07, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health
June 04, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market
May 22, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance
May 21, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
May 16, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
May 09, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset
May 08, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Announces Leadership Changes
April 16, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects
April 11, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program
April 10, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization
April 07, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
March 31, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904
March 19, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel
March 06, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Progresses Phase II of its AI Initiative with Sarborg
February 20, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model
February 13, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note
February 11, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development
February 07, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence
January 28, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
January 23, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline
January 22, 2025
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics
December 12, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
November 21, 2024
Approval of composition of matter patent in key jurisdiction underscores the Company’s commitment to maximize future out-licensing value
From
Conduit Pharmaceuticals
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.